

Correspondence

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Editorial comment in the form of a Letter to the Editor is invited; however, it should not exceed 800 words, with a maximum of 10 references and no more than 2 figures (submitted as camera ready hard copy per Journal Guidelines) or tables and no subdivision for an Abstract, Methods, or Results. Letters should have no more than 4 authors. Full name(s) and address of the author(s) should accompany the letter as well as the telephone number, fax number, or E-mail address.

Contact: The Managing Editor, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto, ON CANADA M4W 3L4. Tel: 416-967-5155; Fax: 416-967-7556; E-mail: jrheum@jrheum.com Financial associations or other possible conflicts of interest should always be disclosed.

Extraarticular Rheumatoid Arthritis and Drug-Induced Syndromes: Understanding the Role of Tumor Necrosis Factor Inhibitors

To the Editor:

I read with great interest the article by Jarrett, *et al*¹, on a case series of 8 patients with rheumatoid arthritis (RA) who developed systemic vasculitis after several infusions with infliximab. The authors implicate an etiopathogenetic role for infliximab in the induction of the systemic vasculitis.

Although infliximab seems the most plausible culprit, it is striking that of their 8 patients, 5 also were treated with leflunomide. Since the introduction of leflunomide on the market, several reports have been published making notice of cases of vasculitis, some with a fatal outcome^{2,3}. Therefore, considering infliximab here as the one and only agent responsible for the vasculitis cases of Jarrett, *et al* denies a role for leflunomide — or possibly the combination of infliximab and leflunomide — which could have accounted for some of their cases. In this respect, it is relevant for the reader to know whether the authors have continued treatment with leflunomide; only by reading the table is the reader informed about continuation of leflunomide in Patient 8.

GEORGE A. W. BRUYN, MD, PhD, Department of Rheumatology, Medisch Centrum Leeuwarden, 8934 AD Leeuwarden, The Netherlands. E-mail: gawbruy@wxs.nl

REFERENCES

1. Jarrett SJ, Cunnane G, Conaghan PG, *et al*. Anti-tumor necrosis factor- α therapy-induced vasculitis: case series. *J Rheumatol* 2003; 30:2287-91.
2. Bruyn GAW, Griep EN, Korff KJ. Leflunomide for active rheumatoid arthritis [letter]. *Lancet* 1999; 353:1883.
3. Bruyn GAW, Veenstra RP, Halma C, Grond J. Anti-glomerular basement membrane antibody-associated renal failure in a patient with leflunomide-treated rheumatoid arthritis. *Arthritis Rheum* 2003; 48:1164-5.

To the Editor:

We read with great interest the article by Jarrett, *et al* on a case series of 8 patients with rheumatoid arthritis (RA) who developed vasculitic lesions while undergoing anti-tumor necrosis factor (TNF) therapy¹. The authors suggest this could indicate a drug-induced syndrome, and discuss various mechanisms through which anti-TNF agents could cause the development of vasculitis. They emphasize the importance of watchfulness, given the risk of rare but serious adverse events in patients receiving such therapy. While we agree that patients receiving such treatment should be carefully monitored, and all serious events noted, we think some of the conclusions drawn by the authors warrant further discussion.

It is well known that a subset of patients with RA develop severe extraarticular disease manifestations, including vasculitis². We recently reported that patients with progressive early arthritis, marked by early disability, are at increased risk of developing severe extraarticular manifestations³. Most patients who receive TNF inhibitors have more severe and progressive disease, and have usually failed a number of other antirheumatic agents. This means that such patients would be expected to have an elevated baseline risk of developing RA-associated vasculitis. Indeed, the first 3 patients reported by Jarrett, *et al* have a clinical history compatible with systemic rheumatoid vasculitis. They all improved after treatment with cyclophosphamide and methylprednisolone, which has been shown to be an appropriate treatment for rheumatoid vasculitis⁴. That infliximab was withheld prior to improvement thus certainly does not prove that the lesions were drug-induced. An alternative interpretation would be that although infliximab had a major effect on synovitis in 2 of the patients, it failed to prevent the development of vasculitis.

Of the remaining 5 patients, the diagnosis of vasculitis is doubtful in 3 cases. One patient developed a rash that is described as pustular, and another had extensive urticaria. No evidence for vasculitis is presented. A third patient had an episode of focal cerebral ischemia, which could be due to vasculitis, but also to a thromboembolic event on the basis of atherosclerotic vascular disease. Although cerebrovascular disease would, generally speaking, be unusual in a 45-year-old man, it has been shown that severe RA with persistently active disease predisposes to cardiovascular events⁵. In any event, the proposed link to infliximab is by no means self-evident. It has recently been shown that the incidence of cardiovascular disease actually tends to be lower in patients treated with anti-TNF therapy than in patients with RA in general⁶. This could reflect a beneficial effect of aggressive antirheumatic treatment on the risk of cardiovascular events in patients with RA.

Rheumatoid vasculitis may improve after anti-TNF therapy. Several case series of refractory rheumatoid vasculitis responding to TNF inhibition have recently been published^{7,8}. On the other hand, it has been reported that scleritis may develop in patients with RA whose joint disease was controlled by TNF-blocking agents⁹. As in the first 3 cases reported by Jarrett, *et al*, the development of this severe extraarticular manifestation suggests that successful anti-TNF therapy for synovitis does not exclude the development of disease-associated extraarticular disease.

Leukocytoclastic vasculitis during treatment with infliximab has been reported in a patient with Crohn's disease¹⁰. This, and the very interesting recurrence of an infliximab-induced cutaneous vasculitic rash in 2 patients rechallenged with etanercept in the case series reported by Jarrett, *et al*, indicates that idiosyncratic vasculitic reactions may result from treatment with agents directed against TNF. Apparently, such reactions seem to be limited to cutaneous lesions. We suggest that so far no evidence has been presented for a direct role of TNF inhibitors in the development of systemic rheumatoid vasculitis with multiorgan involvement.

CARL TURESSON, MD, PhD; ERIC L. MATTESSON, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. E-mail: turesson.carl@mayo.edu

REFERENCES

1. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor- α therapy-induced vasculitis: case series. *J Rheumatol* 2003;30:2287-91.
2. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. *J Rheumatol* 2002;29:62-7.
3. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis* 2003;62:722-7.
4. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. *Am J Med* 1984;76:377-84.
5. Wallberg-Jonsson S, Johansson H, Öhman M-L, Rantapää-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. *J Rheumatol* 1999;26:2562-71.
6. Jacobsson LTH, Turesson C, Gulfe A, et al. Low incidence of cardiovascular events in rheumatoid arthritis patients treated with TNF-blockers [abstract]. *Arthritis Rheum* 2003;48 Suppl:S241.
7. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology Oxford* 2002;41:1126-32.
8. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. *Ann Rheum Dis* 2003;62:587-8.
9. Smith JS, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. *Arthritis Care Res* 2001;45:252-7.
10. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. *J Clin Gastroenterol* 2003;36:411-3.

Dr. Jarrett, *et al* reply

To the Editor:

Dr. Bruyn makes an important point with respect to the cases of vasculitis. There was an overrepresentation of leflunomide partly because we were studying patients who had gone through an escalating protocol that ended with leflunomide.

However, he is right to suggest that a specific role for leflunomide with vasculitis cannot be excluded. In view of this possibility we did stop leflunomide in nearly all cases, and in several cases washed-out with cholestyramine. These details were not included for the sake of brevity. Obviously the induction of this vasculitis may relate to the high prevalence of antinuclear antibodies seen in patients treated with leflunomide and infliximab¹.

Drs. Turesson and Matteson make some very interesting points regarding the development of vasculitis with anti-TNF therapy. We agree that certain of the patients described had severe rheumatoid arthritis (RA) that would have put them at risk of extraarticular manifestations. We also agree that as patients with severe longterm disease they would have failed multiple therapies. However, importantly, despite this long history of severe disease up until the time of anti-TNF therapy, these patients had had no significant extraarticular manifestations. Furthermore, these were dramatic examples of immune reactions. We have a very large catchment population and many thousand RA patients on therapy with severe disease. Despite this, the incidence of acute vasculitis has diminished dramatically, presumably due to more aggressive therapy, cessation of smoking, and other gen-

eral improvements in health. The patients reported here represent a majority of the patients with recent presentations of vasculitis.

We specifically described Case 1 as rheumatoid vasculitis because of the long duration of disease, male sex, rheumatoid factor positivity, and nodular disease, all of which are significant risk factors for the development of vasculitis, and thus agree with Turesson, *et al*. We also made the point that in this case continuation of anti-TNF therapy may be desirable. We referred to correspondence from the drug company describing this phenomenon and referenced an article in which cutaneous vasculitis improved with alternative therapy. For Cases 2 and 3, anti-TNF improved the synovitis, but vasculitis still developed. Importantly, these cases developed early in the disease, i.e., within 12 months of onset of symptoms. There was a striking correlation between serological changes and development of vasculitis.

In Cases 6 and 7 the diagnosis was made by clinicians experienced in the diagnosis of vasculitis, while in Case 8 the neuroradiologist diagnosed definite vasculitis, and an extensive search for thromboembolic causes was undertaken, with no significant risk factor identified in a previously fit 45-year-old.

In the 2 cases with biopsy-proven leukocytoclastic vasculitis — we agree that one patient appears to be a purely local reaction that reoccurred on rechallenge with a different agent; in the second case the rash was associated with a change in serology with the development of antinuclear factor and perinuclear anticytoplasmic antibodies (although we accept there was no change in PR3), which point to a systemic reaction.

The improvement with cyclophosphamide and methylprednisolone is unhelpful in distinguishing drug-induced from disease-related vasculitis. We also agree that the improvements seen on withholding a drug do not provide evidence for causation.

Overall, the cases presented were of a spectrum from vasculitic rashes to systemic vasculitis. We discussed the potential mechanisms and accepted that we could not ascribe causality to all. However, we were struck by the number of cases associated with anti-TNF therapy, especially against the falling incidence of rheumatoid vasculitis.

The fact that anti-TNF has been proposed as therapy for vasculitis was the major reason for publishing the clinical course of these patients. In support of the drug-induced nature of this disease was the change in autoreactivity with development of autoantibodies compatible with a cause for the vasculitis. We feel it is important that clinicians are aware that a presentation of vasculitis in patients receiving TNF could be drug-induced.

STEPHEN J. JARRETT, BSc, MRCP, Research Fellow; GAYE CUNNANE, PhD, MRCP, Senior Lecturer in Rheumatology; PHILIP G. CONAGHAN, MBBS, FRACP, Senior Lecturer in Rheumatology; SARAH J. BINGHAM, MA, MRCP, Research Fellow; MAYA H. BUCH, MRCP, Research Fellow; MARK A. QUINN, MChB, MRCP, Lecturer in Rheumatology; PAUL EMERY, MA, MD, FRCP, ARC, Professor of Rheumatology Lead Clinician, University of Leeds, Department of Rheumatology, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, United Kingdom. E-mail:p.emery@leeds.ac.uk

REFERENCE

1. Bingham SJ, Buch MH, Smith S, Barcelos A, Kerr M, Emery P. Universal induction of auto-immunity in patients with RA treated with infliximab and leflunomide. *Arthritis Rheum* 2004; (in press).

Hormone Replacement Therapy in Rheumatoid Arthritis

To the Editor:

I read with great interest the article by Forsblad d'Elia, *et al* in the July issue¹. The authors note that the highest incidence of developing rheumatoid arthritis (RA) coincides with the menopause. Unfortunately, that also constitutes a risk factor for developing coronary artery disease.

Cardiovascular death is considered the leading cause of mortality in patients with RA and is responsible for about half the deaths observed in RA cohorts². Further, the increased incidence of cardiovascular events in patients with RA is independent of traditional risk factors³. Corticosteroids prescribed in RA may also increase this risk.

Even though the results presented in this article are interesting, they do not influence clinical management of RA. The authors state that no serious side effects were noted with hormone replacement therapy (HRT), but fail to mention how, when, and with what measures these were ascertained in the Methods section. Using HRT as a supplement to conventional therapy in the management of postmenopausal women with RA, who are already at increased risk of cardiovascular events and malignancy, would be unjustifiable in view of the results of recent trials of HRT use among healthy postmenopausal women⁴.

MEENAKSHI JOLLY, MD, Chief, Section of Rheumatology, Advocate Christ Medical Center, Oak Lawn, Illinois, USA

REFERENCES

1. Forsblad d'Elia H, Larsen A, Mattson L-A, et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. *J Rheumatol* 2003;30:1456-63.
2. Goodson N. Coronary artery disease and rheumatoid arthritis. *Curr Opin Rheumatol* 2002;14:115-20.
3. Del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737-45.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-33.

Drs. Forsblad d'Elia and Carlsten reply

To the Editor:

We thank Dr. Jolly for the valuable comments about our study, which assessed the effects of hormone replacement therapy (HRT) on the course of rheumatoid arthritis (RA) and bone mineral density (BMD) in postmenopausal women¹. To summarize, HRT decreased clinical and laboratory signs of disease activity, improved BMD, and indicated a joint protective effect. The patients were examined clinically and had a mammography before entry and yearly thereafter. No serious side effects were recorded in our study with a limited number of participants during the 2 study years. In an investigation designed to evaluate the effect of HRT on cardiovascular events and breast cancer incidence in RA, a larger trial would be needed.

We note our study was conducted and the manuscript was submitted before the Women's Health Initiative study² was published. No overall increase in the rate of coronary heart disease (CHD) events was found in the HRT group in the previously published HERS I trial in women with established CHD³.

We do not think it is possible to generalize the results from studies of healthy postmenopausal women, for instance the women in the WHI trial, to patients with RA, a chronic inflammatory disease, since, as Dr. Jolly writes, the increased incidence of cardiovascular events in patients with RA is independent of traditional risk factors. Instead, the systemic inflammation seems to be of large importance in the development of CHD in RA⁴. In our study, the disease activity was reduced in the HRT group assessed by reduction in erythrocyte sedimentation rate and orosomucoid, and increase in the hemoglobin level. We also found that serum levels of soluble interleukin 6 (IL-6) receptor, an agonist to IL-6, decreased in the HRT group⁵. Also, high disease activity has been shown to be associated with increased risk of developing amyloidosis⁶ and with the occurrence of lymphoma in RA⁷, emphasizing the importance of reducing the systemic inflammation.

Accordingly, one may hypothesize that HRT, through its effects on systemic inflammation, theoretically might have a positive influence on outcomes associated with systemic inflammation in postmenopausal women with RA. This speculation can only be confirmed in larger clinical trials.

HRT, composed of estrogens often in combination with progestogens, influences the endocrine and immune system in a multifaceted way not yet completely understood. Hopefully, selective estrogen receptor modulators with potent antiarthritic and antiinflammatory effects, lacking the side effects associated with conventional HRT, would be developed. In the meantime, we agree with Dr. Jolly that there is a need to be cautious about HRT in view of recent trials^{2,8}. We therefore believe that treatment of postmenopausal RA patients with HRT has to be individualized for any given patient.

HELENA FORSBLAD d'ELIA, MD, PhD; HANS CARLSTEN, MD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden

REFERENCES

1. Forsblad d'Elia H, Larsen A, Mattsson LA, et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. *J Rheumatol* 2003;30:1456-63.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-33.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA* 1998;280:605-13.
4. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. *Circulation* 2003;108:2957-63.
5. Forsblad d'Elia H, Mattsson LA, Ohlsson C, Nordborg E, Carlsten H. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor. *Arthritis Res Therapy* 2003;5:R202-R9.
6. Tiitinen S, Kaarela K, Helin H, Kautiainen H, Isomaki H. Amyloidosis — incidence and early risk factors in patients with rheumatoid arthritis. *Scand J Rheumatol* 1993;22:158-61.
7. Baecklund E, Ekblom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. *BMJ* 1998;317:180-1.
8. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362:419-27.

Origins of Erosive Arthritis

To the Editor:

Rothschild, *et al* have documented a fascinating inverse link between rheumatoid arthritis (RA) and tuberculosis (TB)¹. Studying the 2 diseases in the Archaic and Early Woodland period of North America, they conclude that TB offers protection against the development of RA. Could they have as readily concluded that RA protects against TB?

Immune resistance to *Mycobacterium tuberculosis* derives primarily from the Th1 arm of the immune system². A Th1-charged system, although predisposing to RA³, may be expected to deter the tubercle bacillus, a rapid Th1-type cytokine release overwhelming the pathogen before it gains a foothold.

One percent of the world's population has RA⁴. The lack of racial, geo-

graphic, or climatic clustering is consistent with a disease having global survival value. *M. tuberculosis* is global and one of the greatest disease scourges of humans, causing more deaths annually than any other human pathogen⁵. Over 8 million new cases of TB and 2 million deaths occur annually. The vigorous mammalian immune response to antigens associated with the mycobacterium species, a phenomenon long appreciated by the response to Freund's complete adjuvant², is evidence of the frantic posturing of mammals toward the mycobacterium. An immune system such as that underlying RA, poised and quickly triggered into a Th1-type of immune response, would offer deterrence. However, the price to pay for such a defense would be an immune system poised for robust Th1-weighted responses not only against the tubercle bacillus but also against innocuous agents or even toward micro-injury and manifesting as inflammatory joint damage, i.e., RA.

In *The Journal* last year is a report from Spain that the risk of TB is increased 4-fold in patients with RA⁶. Although this appears on the surface to be in conflict with the Rothschild report it is, on the contrary, consistent with it. Unlike patients with the rheumatoid diathesis, patients with overt clinical disease are debilitated and are treated with drugs such as corticosteroids that specifically target and diminish the Th1 cytokine release that predisposes to RA and protects against TB.

Although the skew toward a Th1 pattern of cytokine response that predisposes to RA may have had survival value at one time, drugs effective against TB have for the most part eliminated that edge. The door may now be open to the pursuit of creative means of reversing this survival mechanism and thereby RA.

HUGH McGRATH Jr, MD, Louisiana State University Health Care Center, 1542 Tulane Avenue, New Orleans, Louisiana 70112, USA.
E-mail: hmcgra@lsuhsc.edu

REFERENCES

1. Rothschild BM, Rothschild C, Helbling M. Unified theory of the origins of erosive arthritis: conditioning as a protective/directing mechanism? *J Rheumatol* 2003;30:2095-102.
2. Haanen JBAG, de Waal Malefijt R, Res PCM, et al. Selection of a human helper type 1-like T cell subset by mycobacteria. *J Exp Med* 1991;174:583-92.
3. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. *Arthritis Rheum* 1997;40:2105-15.
4. Wolfe AM. The epidemiology of rheumatoid arthritis: A review. I. Surveys. *Bull Rheum Dis* 1968;19:518-23.
5. World Health Organization. 2001 Global tuberculosis control. WHO Report. WHO/CDS/TB/2001, 287:173, 2001. Geneva: WHO; 2001.
6. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol* 2003;30:1436-9.

Dr. Rothschild replies

To the Editor:

Dr. McGrath's considered analysis of our recent article¹ is very much appreciated. The key to understanding is often predicated upon asking the right question. Delineation of the time course of recognition of rheumatoid arthritis (RA) raised the possibility that it actually originated as a New World disease. Affirmative answer to that question² and observation of its North American distribution pattern over time³ raised the possibility that RA is a vector-derived disease⁴. The geographic dichotomy between distribution of RA and that of tuberculosis in ancient North America⁵ suggested that perhaps the wrong question was being asked. Rather than ask what is directly causing RA, perhaps it is more appropriate to ask if tuberculosis acts as a conditioning agent. If RA and spondyloarthritis are related, perhaps this conditioning agent is the determinant for which disease occurs.

Perhaps absence of a tuberculosis-related factor is a necessary condition for occurrence of RA.

McGrath asks if our initial question requires further revision. Could the presence of RA have prevented occurrence of tuberculosis? It is unclear how the presence of RA in a relatively few individuals could alter occurrence of tuberculosis in other members of that population. Alteration of immune response in the affected individual might alter their own susceptibility, but it is unclear to me how this would affect "herd immunity" and therefore population resistance to tuberculosis. Further, there is no epidemiologic evidence that Amerindians (in the RA catchment area) were ever actually exposed to tuberculosis. There is certainly no evidence that they came into contact with infected animals¹.

McGrath notes that this question does not negate our hypothesis, but actually extends it to address a further issue: Is tuberculosis less common among individuals with RA? If so, then does RA have a global survival value? It is intriguing that this question is raised. First, such assessment has been offered for spondyloarthritis, for which there has been clear demonstration of geologic time longevity⁵, panspecific mammalian distribution⁶, and geometric increase in frequency over time^{7,8}. Second, it requires interpretation of reports, such as that of the EMECAR Study group⁹. McGrath very appropriately points out the confounding effect of contemporary therapeutics, the very reason why study of ancient populations (free of effects of contemporary therapeutics) provides such valuable and otherwise unattainable insights¹⁰. However, analysis of frequency reports⁹ also requires reconsideration of the clinical issue of diagnostic lumping and splitting¹¹. Some rheumatologists classify as having RA individuals that others would classify as having spondyloarthritis. We suggested very specific criteria¹¹ for classification of individuals with inflammatory arthritis as having RA. They include periarticular osteopenia and marginally (not subchondrally distributed) symmetrical polyarticular erosions, in the absence of axial (odontoid disease excepted) involvement or of peripheral joint fusion. Application of such limiting criteria (to individuals with inflammatory arthritis who develop tuberculosis) will perhaps allow confident clarification of the question — does RA protect the individual from infection with tuberculosis?

The clear recognition that much of our current therapeutics predispose to infection is one of the factors propelling the ongoing effort to uncover new approaches. Progress will likely derive from learning to ask the right question.

BRUCE ROTHSCHILD, MD, Arthritis Center of Northeast Ohio, 5500 Market, Youngstown, Ohio 44512, USA. E-mail: bmr@neucom.edu

REFERENCES

1. Rothschild BM. Unified theory of origins of erosive arthritis: Conditioning as a protective/directing mechanism? *J Rheumatol* 2003;30:2095-102.
2. Rothschild BM, Turner KR, DeLuca MA. Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. *Science* 1988;241:1498-501.
3. Rothschild BM, Woods RJ, Rothschild C, Sebes JI. Geographic distribution of rheumatoid arthritis in ancient North America: Implications for pathogenesis. *Semin Arthritis Rheum* 1992;22:181-7.
4. Rothschild BM. Rheumatoid arthritis at a time of passage. *J Rheumatol* 2001;28:245-50.
5. Rothschild BM. Origin of spondyloarthritis in the Jurassic. *Lancet* 2002;360:1454.
6. Rothschild BM, Rothschild C. Spondyloarthritis as a trans-mammalian phenomenon, reproducible in its manifestations across species lines. *J Paleopathol* 2000;11:103-4.
7. Rothschild BM, Prothero DR, Rothschild C. Origins of spondyloarthritis in Perissodactyla. *Clin Exp Rheumatol* 2001;19:628-32.
8. Rothschild BM, Rothschild C. Epidemic of spondyloarthritis in

baboons. *J Med Primatol* 1996;25:69-70.

9. Carmona L, Hernandez-Garcia C, Vadillo C, et al, EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol* 2003;30:1436-9.
10. Rothschild BM, Martin LD. *Paleopathology: Disease in the fossil record*. London: CRC Press; 1993.
11. Rothschild BM. Two faces of "rheumatoid arthritis": Type A versus type B disease. *J Clin Rheumatol* 1997;3:334-8.

Comparison Between Ultrasound and Magnetic Resonance Imaging of Achilles Tendon Enthesopathy in Patients with Psoriasis

To the Editor:

We have read with great interest the report by Kamel and coworkers¹ on the diagnostic evaluation of heel enthesitis in patients with seronegative arthropathy. In particular, we found the comparison between ultrasound (US) and magnetic resonance (MR) data very stimulating.

Indeed, in a recent study on Achilles tendinitis in psoriatic subjects² we demonstrated in 59 patients and 50 healthy volunteers that US is a safe and reliable method to detect the frequent changes in Achilles tendon and peritendinous tissues that may be associated with the enthesopathic involvement. Based on our experience and on data from the literature^{3,7}, we are now conducting a new study to identify ever-earlier evidence of enthesopathy in psoriatic subjects with and without arthropathy, and to optimize use of the various imaging techniques to detect relevant signs of disease. US evaluation is being integrated with color Doppler and unenhanced and contrast-enhanced MR examination of Achilles tendon.

We are currently evaluating data from 22 psoriatic patients (17 men and 5 women; age range 19–72 years, mean 48; Psoriasis Area and Severity Index⁸ scores between 8.6 and 47.1, mean 14), 16 of whom have been diagnosed with psoriatic arthropathy. Subjects were studied with an Aplio (Toshiba) US machine, using an 8–13 MHz multifrequency linear transducer, equipped with color Doppler to detect possible intra- or peritendinous vascular changes. Patients also underwent MR scanning in a superconducting 0.2 Tesla E-Scan XQ Esaote magnet using a surface coil. T1 and T2 weighted sequences were acquired on axial and sagittal planes, and gradient echo and short-time inversion recovery sequences on the sagittal plane. Axial and sagittal T1 weighted sequences were acquired after administration of a 0.1 mmol/kg bw bolus of dimeglutine gadopentate (Magnevist, Schering, Berlin, Germany).

Preliminary results confirm the sensitivity of US in depicting early signs of Achilles tendon involvement; in particular, intratendinous microcalcifications (the outcome of previous degenerative tendon damage now in reparative evolution) were identified in 6 patients, and signs of bursitis in 6 more. MR was less sensitive, especially regarding identification of microcalcifications (not detected in any patient), whereas the 2 methods yielded similar results in the evaluation of tendon changes (enlargement and degenerative areas) and peritendinous thickening; in 2 patients, however, US allowed detection of degenerative changes measuring less than 3 mm that were not seen with MR.

The contribution of color Doppler does not seem significant; this is not surprising, since vascular changes are typical of acute inflammation, and most of the patients enrolled to date receive an antiinflammatory therapy for their arthropathy, which might mitigate inflammatory changes. Indeed, and interestingly, post-contrast MR images did not significantly improve on unenhanced data.

Our preliminary results confirm the findings of Kamel and coworkers, despite differences in the sample studied. US examination conducted by experienced operators using machines equipped with multifrequency probes — especially high frequencies and thus high spatial resolution — is at present superior to MR in detecting early enthesopathic changes of

Achilles tendon, particularly with low-field magnets. US should be considered the imaging technique of choice for early diagnosis, disease evaluation, and followup of psoriatic patients with suspected Achilles tendon enthesopathy.

CLARA De SIMONE, MD, Department of Dermatology; FLAVIO Di GREGORIO, MD, Department of Radiology; FABIO MAGGI, MD, Department of Radiology, Università Cattolica del Sacro Cuore, Rome, Italy.

REFERENCES

1. Kamel M, Eid H, Mansour R. Ultrasound detection of heel enthesitis: a comparison with magnetic resonance imaging. *J Rheumatol* 2003;30:774-8.
2. De Simone C, Guerriero C, Giampetruzzi AR, et al. Achilles tendinitis in psoriasis: clinical and sonographic findings. *J Am Acad Dermatol* 2003;49:217-22.
3. Richards PJ, Dheer AK, McCall IM. Achilles tendon (TA) size and power Doppler ultrasound changes compared to MRI: a preliminary observational study. *Clin Radiol* 2001;56:843-50.
4. Balint PV, Sturrock RD. Inflamed retrocalcaneal bursa and Achilles tendinitis in psoriatic arthritis demonstrated by ultrasonography. *Ann Rheum Dis* 2000;59:931-3.
5. Schweitzer ME, Karasick D. MR imaging of disorders of the Achilles tendon. *AJR Am J Roentgenol* 2000;175:613-25.
6. Movin T, Kristoffersen-Wiberg M, Rolf C, et al. MR imaging in chronic Achilles tendon disorder. *Acta Radiol* 1998;39:126-32.
7. Shalabi A, Kristoffersen-Wiberg M, Papadogiannakis N, Aspelin P, Movin T. Dynamic contrast-enhanced MR imaging and histopathology in chronic Achilles tendinosis. A longitudinal MR study of 15 patients. *Acta Radiol* 2002;43:198-206.
8. Fredericksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. *Dermatologica* 1978;157:238-44.

Drs. Kamel, et al reply

To the Editor:

We thank Dr. De Simone and coworkers for their valuable data and interest in our work¹. Enthesopathy is an evolving area for applied clinical research. The diagnosis of enthesitis in clinical practice is difficult, and typical conventional radiography was almost not helpful. Too many patients are underdiagnosed and/or misdiagnosed because early pathological changes of enthesitis in the different types of spondyloarthropathies are not detected^{1,3}.

We agree that ultrasound (US) imaging proved to be more sensitive and accurate than other imaging modalities in detecting enthesopathy. US examinations usually show reliable evidence for: loss of fibrillar echo pattern, lack of homogenous pattern with flaring of tendon margins, irregular fusiform tendon thickening, and hyperechoic intratendinous lesions with ill defined focal defects filled with a mixture of fluid, fat, and/or granulation tissue indicating fatty degeneration^{1,8}. Further, US shows very early signs of intratendinous calcification that MRI cannot^{1,3}.

US provides data that help in the diagnosis and identification of different pathological and biomechanical changes in the Achilles tendon^{1,3,7,8}. We are currently studying enthesitis at other insertion sites such as the patellar knee tendon², greater trochanter, iliac crest, deltoid tendon, elbow epicondyles, manubrium sterni, and collateral ligaments of knees and ankles. We believe these studies will provide interesting data for more accurate diagnosis in patients with different types of spondyloarthropathies, particularly psoriasis, Reiter's disease, ankylosing spondylitis, and ulcerative colitis.

We also believe that color Doppler will be more beneficial in detecting early pathological changes in the synovium rather than in the tendons. We suggest that a multicenter study in collaboration with other colleagues would be beneficial.

MOHAMED KAMEL, MD, PhD, FACR; HAZEM EID, MD;
RAMY MANSOUR, MSc; MOHAMED ABBADY, MSc, Rheumatology
and Radiology Departments, Al-Azhar University, Cairo, Egypt; and Dr.
Fakhery Hospital, Al-Khobar, Saudi Arabia

REFERENCES

1. Kamel M, Eid H, Mansour R. Ultrasound detection of heel enthesitis: a comparison with magnetic resonance imaging. *J Rheumatol* 2003;30:774-8.
2. Kamel M, Eid H, Mansour R. Ultrasound detection of knee patellar enthesitis: A comparison with MRI. *Ann Rheum Dis* 2004;63:213-4.
3. De Simone C, Guerriero C, Gimapetruzzi AR, et al. Achilles tendonitis in psoriasis: clinical and sonographic findings. *J Am Acad Dermatol* 2003;49:217-22.
4. Kamel M, Moghazy K, Eid H, Mansour R. Ultrasonographic detection of de Quervain's disease. *Ann Rheum Dis* 2002;61:1034-5.
5. Kamel M, Kotob H. Ultrasonographic assessment of local steroid injection in Tietze's syndrome. *Br J Rheumatol* 1997;36:547-50.
6. Grassi W, Fillippucci A, Farina A, Salaffi F, Cervini C. Sonographic imaging of tendons. *Arthritis Rheum* 2000;43:969-76.
7. Gibbon WW, Cooper JR, Radcliffe GS. Distribution of sonographically detected tendon abnormalities in patients with a clinical diagnosis of chronic Achilles tendinosis. *J Clin Ultrasound* 2000;28:61-6.
8. Fornage BD, Rifkin Md, Touche D, Segal PM. Sonography of the patellar tendon: preliminary observations. *AJR Am J Roentgenol* 1984;143:179-82.

Silicone Breast Implants

To the Editor:

In his recent editorial¹, Dr. Vasey and his colleagues made reference to our study of symptom-reporting in women with cosmetic breast implants compared with women with breast reduction surgery². In the editorial, Dr. Vasey, *et al* misunderstood our study population and the study conclusions, as they did in an earlier letter on the same study^{3,4}. In the Abstract, Results, and Discussion sections of our earlier report², we explicitly state that the study population contained women with both silicone-filled (77%) and saline-filled (23%) implants. Nowhere do we present analyses exclusively for women with ruptured silicone implants, as reported in Table 1 of Dr. Vasey's editorial.

In our study, we did examine whether filler type (silicone or saline) and implant size (larger or smaller than the median of the respective implant type) influenced the associations with the symptoms. Risks were not higher among women with larger silicone implants, and thus more silicone gel, compared with smaller implants, and thus less silicone gel; moreover, women with saline implants had twice the rate of local complications compared with women with silicone implants⁵.

Contrary to the implications of Vasey, *et al*, no epidemiologic study has found evidence for a new disease or syndrome related to silicone implants^{6,7}.

JON P. FRYZEK, PhD; JOSEPH K. McLAUGHLIN, PhD, International
Epidemiology Institute, 1455 Research Blvd, Suite 550,
Rockville, Maryland 20850, USA

REFERENCES

1. Vasey FB, Alireza Zarabadi S, Seleznick M, Ricca L. Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined [editorial]. *J Rheumatol* 2003;30:2092-4.
2. Fryzek JP, Signorello LB, Hakelius L, et al. Self-reported symptoms among women after cosmetic breast implants and breast reduction surgery. *Plast Reconstr Surg* 2001;107:206-13.
3. Vasey FB, Mills CR, Wells AF. Silicone breast implants and fibromyalgia [letter]. *Plast Reconstr Surg* 2001;108:2165-8.
4. Fryzek JP, McLaughlin JK, Nyren O. Response to "Silicone breast implants and fibromyalgia" [letter]. *Plast Reconstr Surg* 2001;108:2165-8.
5. Fryzek JP, Signorello LB, Hakelius L, et al. Local complications and subsequent symptom reporting among women with cosmetic breast implants. *Plast Reconstr Surg* 2001;107:214-21.
6. Holmich LR, Kjoller K, Fryzek JP, et al. Self-reported diseases and symptoms by rupture status among unselected Danish women with cosmetic silicone breast implants. *Plast Reconstr Surg* 2003;111:723-32.
7. Kjoller K, Friis S, Mellemkjaer L, et al. Connective tissue disease and other rheumatic conditions following cosmetic breast implantation in Denmark. *Arch Intern Med* 2001;161:973-9.

Dr. Vasey replies

To the Editor:

We appreciate the work done by Fryzek and McLaughlin in improving understanding of clinical systemic and local symptoms in women with both saline-filled and silicone gel-filled breast implants^{1,2}. They rightly point out that the title of our Table 1³ should not have included "with rupture." We agree rupture is not required before systemic symptoms develop.

The writers' final note, "no epidemiologic study has found evidence for a new disease," deserves comment. Elsewhere⁴ they observe, "It is not possible to conduct a rigorous epidemiological study without first having a validated and reliable definition of the disease under investigation." Our editorial was a plea for a new disease definition that epidemiologists could study. We feel strongly that prevalence of symptom studies show statistically increased prevalence of symptoms in women with silicone breast implants compared with controls, as summarized in our editorial³.

If the flu were undefined it would not exist in the epidemiological world, but in the real world millions of people have it.

FRANK B. VASEY, MD, Professor and Director, Division of
Rheumatology, University of South Florida, Tampa, Florida, USA

REFERENCES

1. Fryzek JP, Signorello LB, Hakelius L, et al. Self-reported symptoms among women after cosmetic breast implants and breast reduction surgery. *Plast Reconstr Surg* 2001;107:206-13.
2. Fryzek JP, Signorello LB, Hakelius L, et al. Local complications and subsequent symptom reporting among women with cosmetic breast implants. *Plast Reconstr Surg* 2001;107:214-21.
3. Vasey FB, Alireza Zarabadi S, Seleznick M, Ricca L. Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined [editorial]. *J Rheumatol* 2003;30:2092-4.
4. Fryzek JP, McLaughlin JK, Nyren O. Reply to letter. *Plast Reconstr Surg* 2001;108:2166-7.



Giant Cell Arteritis in a Patient Taking Etanercept and Methotrexate

To the Editor:

I describe the occurrence of giant cell arteritis (GCA) in an elderly woman with long-standing seropositive rheumatoid arthritis (RA), treated for 2 years with etanercept 25 mg twice weekly and methotrexate 7.5 mg weekly. Since etanercept and infliximab were approved for treatment of RA, there has been one report of noncaseating granulomas in pulmonary parenchyma¹ and vasculitis with increased nodulosis², and several reports of reactivation of latent tuberculosis in patients taking infliximab or etanercept³. These and other complications of tumor necrosis factor- α (TNF- α) receptor-blocking therapy involving activated endothelial cells and granuloma formation suggest a common mechanism of inflammation in susceptible patients.

In summer 2002, a 79-year-old Caucasian woman with RA presented with left jaw pain, so severe that she would not open her mouth to eat. There was associated ear pain and a sore throat. Evaluation by our dental service showed no lesion. The next week when she came into clinic for her injections, she reported worsening pain over the left temporal area. There was no antecedent trauma, and no history of temporomandibular joint involvement in her disease or previous complaints of pain at this site. Present on examination was a thin-walled, tender left temporal artery, with no erythema. There was no evidence on examination of other systemic vasculitis. A biopsy of the left temporal artery showed GCA (Figure 1). Laboratory studies were remarkable for a rising erythrocyte sedimentation rate, 46 to 86, and negative antinuclear antibodies, and she was hepatitis C antibody negative. No HLA testing was done.




Figure 1. Left temporal artery biopsy revealed GCA in a 79-year-old woman with RA (H & E, $\times 10$).

GCA is commonly reported in association with polymyalgia rheumatica, but it is unusual to see GCA occurring in patients with RA — or at least, it is reported infrequently in the literature. In 1983, 2 groups published cases describing its concurrence, and there has been speculation over the years that RA and GCA may share common pathogenetic mechanisms^{4,6}. Studies in GCA have described TNF I (p55) receptor expression in the intima of the large arteries, with immunohistochemical staining revealing TNF- α on endothelial cells, macrophages, and giant cells⁷.

Etanercept is a soluble TNF receptor, a fusion protein created from human TNF p75 receptor and the Fc portion of human immunoglobulin G1. Binding to soluble TNF- α , this drug effectively blocks receptor activation in RA, resulting in clinical improvement in many patients. In 2002, Cunnane and colleagues showed images of an inflammatory cell infiltrate in a medium-size arterial wall associated with accelerated nodulosis in patients with RA treated with etanercept². Clinical trials in Crohn's disease suggest etanercept is not effective in Th1 mediated inflammatory bowel disease, although infliximab has some record of success⁸. The reason for this discrepancy is unclear. Clinical studies have been undertaken to examine the efficacy of etanercept in Wegener's granulomatosis. The responses here, too, have been variable, suggesting once again that etanercept may not protect against granulomatous vasculitis⁹. In 2003, Tan, *et al* published a letter describing effective treatment of "resistant" GCA with etanercept in an elderly man with clinical polymyalgia rheumatica and biopsy negative temporal arteritis¹⁰.

The experience with our patient raises the question whether individuals undergoing TNF receptor blockade might be more vulnerable to granulomatous vasculitis, or to other infectious complications requiring effective granuloma formation and intracellular killing. Moreland, *et al* recently reported there is no evident impairment of delayed hypersensitivity reactions in patients taking etanercept, that immunoglobulin concentrations are normal, and there was no excessive risk of infection in the people studied¹¹. Clearly, the complications of TNF receptor blockade reported in the literature suggest that at a cellular level, in an aging artery, arteriole, or latent tubercular granuloma, TNF receptor expression and signaling are altered in some way, in some individuals. As clinical trials using anti-TNF agents in granulomatous vasculitis are under way, it is important that clinicians realize that these agents may not be effective in these diseases, and may not protect against them.

MARGARET SETON, MD, Chief of Rheumatology, Cambridge Health Alliance, Assistant Professor of Medicine, Harvard University, Staff Physician, Arthritis Unit, Bulfinch 165, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
E-mail: margaret_seton@hms.harvard.edu

REFERENCES

1. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. *Chest* 2002;122:1858-60.
2. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. *Arthritis Rheum* 2002;47:445-9.
3. Keane J, Gershon S, Wise RP, *et al*. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *New Engl J Med* 2001;345:1098-104.
4. Horslev-Petersen K, Helin P. Coexistence of temporal arteritis and rheumatoid arthritis. *J Rheumatol* 1983;10:831-3.
5. Hall S, Ginsburg WW, Vollertsen RS, Hunder GG. The coexistence of rheumatoid arthritis and giant cell arteritis. *J Rheumatol* 1983;10:995-7.
6. Salvarani C, Cantini F, Boiardi L, Hunder G. Polymyalgia rheumatica and giant-cell arteritis. *New Engl J Med* 2002;347:261-71.
7. Cook A, Gallagher G, Field M. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. *Rheumatol Int* 1997;17:113-8.

8. Podolsky DK. Inflammatory bowel disease. *New Engl J Med* 2002;347:417-29.
9. Stone J, Uhlfelder M, Hellmann D, Crook S, Bedocs N, Hoffman G. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. *Arthritis Rheum* 2001;44:1149-54.
10. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept [letter]. *Ann Rheum Dis* 2003;62:373-4.
11. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. *Clin Immunol* 2002;103:13-21.

Is Measurement of Serum Vascular Endothelial Growth Factor Reliable in Patients with Systemic Sclerosis?

To the Editor:

I read with interest the article by Choi, *et al*¹ reporting serum concentrations of vascular endothelial growth factor (VEGF) in patients with systemic sclerosis (SSc). I bring to your attention some methodological concerns that have arisen.

First, serum VEGF levels do not reflect VEGF synthesis by peripheral tissues, and they are not representative of circulating extracellular VEGF level at the time of sampling. In serum, VEGF levels are several-fold higher than in matched plasma samples, owing to *in vitro* release of VEGF from platelets during blood clotting^{2,3}. Although various blood cells such as granulocytes, monocytes, mast cells, and lymphocytes have been shown to be capable of producing VEGF, these cells are of little importance for the release of VEGF into the circulation^{4,5}. Contradictory results on platelet aggregation in patients with SSc have been reported. *In vitro* studies suggest that platelets from patients with SSc are hyperactive^{6,8}; these observations may justify the increased levels of serum VEGF measured by the authors in patients with SSc compared with healthy controls. CTAD (citrate, theophylline, adenosine, dipyridamole) plasma is recommended for the measurement of circulating extracellular VEGF⁹.

Second, the authors did not report the condition of processing (i.e., force of centrifugation, time and temperature between blood collection and processing). When VEGF levels are measured, standardization in the collection of serum is relevant and it should be declared. VEGF is released from the platelet in serum in a time-dependent manner. Allowing whole blood sample to clot 2 to 6 hours before serum is collected reduces time-dependent, non-uniform release of VEGF⁶. In addition, centrifuging samples at variable centrifugal forces or for variable times can affect platelet activation by mechanical stress, and consequently may influence VEGF levels. The authors suggest that "high VEGF levels may serve as a surrogate indicator of capillary damage in SSc." In a clinical situation, where blood samples are taken and left for variable times before processing, the contribution from the clotting process would effectively rule out the use of serum measurement. However, even if strict uniformity of clotting time is applied to all samples, the large interpersonal variation in generation of VEGF in clotted samples may invalidate the results².

Third, platelet count is significantly correlated to VEGF serum level⁴. When VEGF levels are measured from serum samples, it is advisable to correct the measurement to platelet count¹⁰.

In light of these considerations, I believe the results reported by the authors should be confirmed on plasma samples. The use of plasma samples may improve the value of circulating extracellular VEGF as an indicator of capillary damage in patients with SSc.

SIMONE FERRERO, MD, Department of Obstetrics and Gynaecology, San Martino Hospital, University of Genoa, Largo R. Benzi 1, 16132 Genoa, Italy. E-mail: simone.ferrero@fastwebnet.it

REFERENCES

1. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. *J Rheumatol* 2003;30:1529-33.
2. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. *Clin Sci Lond* 1998;94:395-404.
3. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. *Oncology* 2000;58:169-74.
4. Grutzkau A, Kruger-Krasagakes S, Baumeister H, et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. *Mol Biol Cell* 1998;9:875-84.
5. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. *Ann Surg Oncol* 1998;5:271-8.
6. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. *Scand J Clin Lab Invest* 2002;62:343-50.
7. Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. *Clin Exp Rheumatol* 1984;2:119-23.
8. Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. *Br J Haematol* 1993;84:675-80.
9. Wynendael W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? *Ann Oncol* 1999;10:965-71.
10. Hornbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor analysis in peripheral blood: is the current literature meaningful? *Clin Exp Metastasis* 2002;19:651-63.

Autoantibodies to Bactericidal/Permeability-Increasing Protein and Cathepsin G in Systemic Sclerosis

To the Editor:

In a recent article, Khanna, *et al*¹ suggest that bactericidal/permeability-increasing protein (BPI) and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic antibodies (ANCA) in systemic sclerosis (SSc) or scleroderma. We investigated the prevalence of antibodies to BPI, cathepsin G, myeloperoxidase (MPO), proteinase 3 (PR3), lactoferrin, lysozyme, and elastase using a commercial Combi ELISA kit (Diamedix, Miami, FL, USA). Sera of 20 patients with SSc (7 diffuse form, 13 limited form) were examined. In agreement with the findings of Khanna, *et al*¹, we observed that the prevalences of antibodies to BPI (9/20, 45%) and cathepsin G (11/20, 55%) were higher than those of antibodies to MPO (1/20, 5%), PR3 (4/20, 20%), lactoferrin (4/20, 20%), lysozyme (1/20, 5%), and elastase (2/20, 10%). Similarly, in our sera BPI and cathepsin G antibodies were frequently associated (8/9 and 8/11, respectively).

Recently, performing indirect immunofluorescence (IIF) studies on 115 sera from patients with diffuse (n = 55) and the limited form (n = 60) of SSc we found ANCA positivity in 23 cases (20%)^{2,3}. In accord with Khanna, *et al*, the only fluorescent patterns were the atypical (15.6% of cases) and perinuclear (4.3%) stainings, while cytoplasmic fluorescence was never found. However, our IIF results were obtained employing ethanol and formalin-

fixed human neutrophils (Inova Diagnostics, San Diego, CA, USA) as substrate⁴, while they used only ethanol-fixed human neutrophils.

When we compared^{2,5} the clinical and serological features of cathepsin G, MPO, and PR3 ANCA-positive patients with those of cathepsin G, MPO, and PR3 ANCA-negative patients, we found no correlation. In particular, according to the reports cited^{2,5}, statistical analysis showed no association between cathepsin G positivity and clinical/serological features nor between MPO positivity and kidney involvement.

We confirm the high prevalence of anti-BPI and cathepsin G antibodies and their frequent association in SSc sera. The significance of their presence and that of other ANCA in scleroderma remains unknown.

PANAGIOTIS GRYPLOTIS, PhD, Research Biologist; FRANCO COZZI, MD, Assistant Professor of Rheumatology; AMELIA RUFFATTI, MD, Associate Professor of Rheumatology, Department of Medical and Surgical Sciences, Rheumatology Unit, University of Padova, Policlinico Universitario, Via Giustiniani 2, 35128 Padova, Italy. E-mail: amelia.ruffatti@unipd.it

REFERENCES

1. Khanna D, Aggarwal A, Bhakuni DS, Dayal R, Misra R. Bactericidal/permeability increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. *J Rheumatol* 2003;30:1248-52.
2. Grypiotis P, Ruffatti A, Cozzi F, et al. Prevalence and clinical significance of cathepsin G antibodies in systemic sclerosis [Italian]. *Reumatismo* 2003;55:256-62.
3. Ruffatti A, Grypiotis P, Todesco S. Antineutrophil cytoplasmic antibodies in patients with systemic sclerosis [reply to letter]. *J Rheumatol* 2003;30:2079-80.
4. Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. *Clin Exp Rheumatol* 2000;18:707-12.
5. Ruffatti A, Sinico RA, Radice A, et al. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. *J Rheumatol* 2002;29:918-23.

Gastrointestinal Disease and Psoriatic Arthritis

To the Editor:

Observations suggest that a relationship exists between gastrointestinal (GI) disease and psoriatic arthritis (PsA). A subgroup of patients with PsA has large joint oligoarthritis that is clinically similar to reactive arthritis and the arthritis associated with inflammatory bowel disease (IBD). In addition, microscopic inflammatory changes in the bowel mucosa of patients with active psoriasis and PsA are common^{1,2}. These findings have led to the suggestion that GI disease, as well as skin disease, may act as a portal of entry of causative antigens in PsA³. Despite these observations, the background frequency of GI disease in patients with PsA has not been well documented. This issue has growing relevance given that the treatment of PsA increasingly involves the use of disease modifying drugs that may adversely affect the GI system.

We studied the prevalence of GI disease in a group of patients with PsA.

One hundred three unselected patients with PsA were recruited from general rheumatology outpatient clinics in Oxford, UK. Ethical approval was obtained from the Central Oxford Research Ethics Committee. Patients were considered to have PsA if they had seronegative inflammatory arthritis and psoriasis³. The clinical characteristics of these patients have been reported⁴. A detailed history was taken for the presence of GI disease including a diagnosis of IBD and irritable bowel syndrome (IBS). Patients

were also specifically questioned about symptoms of gluten sensitivity. To further screen for celiac disease, IgA antiendomysial antibodies were tested by direct immunofluorescence in 96 of the patients. The results of antiendomysial antibody testing have been reported⁵, and are included here for completeness. HLA-B27 was tested in 98 patients by polymerase chain reaction with sequence-specific primers. Data were analyzed using contingency tables. The frequency of IBD and IBS in the study patients was compared with that of historical UK controls^{6,7}. P values are expressed as 2-tailed values.

Four of 103 (3.9%) patients had biopsy-proven IBD, compared with the reported prevalence of IBD in the general UK population of 0.4% ($p < 0.001$). There were 3 patients with ulcerative colitis and one with Crohn's disease. All patients with IBD had psoriatic nail and scalp disease. Three had polyarticular disease and one had oligoarticular disease. One patient had significant axial disease, with sacroiliitis on magnetic resonance imaging (but was HLA-B27 negative). HLA-B27 results were available for 3 patients with IBD; all were HLA-B27 negative.

No patient had GI malignancy or celiac disease. Antiendomysial antibodies were negative in all patients. The prevalence of IBS (18%) was comparable to that of the general population.

The most striking finding was the high prevalence of IBD in our patients with PsA: almost 10-fold greater than the general UK population. While this is not an age or sex matched comparison, we believe these results are clinically meaningful. Sampling bias may also lead to an overestimation of the prevalence of IBD in our PsA population. Importantly, our patients were not recruited from an institution with a specialized gastroenterology unit. Clearly, it is impossible to distinguish with complete certainty between patients with PsA and IBD, and patients with enteropathic arthritis and psoriasis. However, all patients recruited into this study met the Moll and Wright criteria for PsA, and were considered to have typical PsA by their usual rheumatologist as well as by the investigators.

Although an increased risk of IBD in patients with PsA has not been widely reported, studies of patients with IBD have shown a high prevalence of psoriasis, ranging from 5.7% to 11.2%^{8,9}. Overall, these data support the hypothesis that common genetic or environmental determinants for IBD, psoriasis, and PsA exist. It is unlikely that HLA-B27 is a clinically significant factor in our patients. Rahman and colleagues have recently reported that the *CARD15 (NOD2)* Crohn's disease susceptibility gene also confers susceptibility to PsA independent of HLA-Cw*0602¹⁰. It would be interesting to study a larger group of patients with IBD and PsA to determine whether shared genetic factors such as *CARD15* gene variants account for this association.

We wish to raise awareness of the association between PsA and IBD. Our data suggest that clinicians should have a high index of suspicion for IBD in their patients with PsA.

LYN WILLIAMSON, MA, MRCP (Oxon), Consultant Rheumatologist; JOANNE L. DOCKERTY, MB ChB, Rheumatology Research Fellow; NICOLA DALBETH, FRACP, Rheumatology Research Fellow; B. PAUL WORDSWORTH, FRCP, Consultant Rheumatologist, Department of Rheumatology, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, United Kingdom. Email: lyn.williamson@smnhst.swest.nhs.uk

Supported by an Oxford District Research Grant. Dr. Dalbeth is the Rose Hellaby Fellow 2002.

REFERENCES

1. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. *J Rheumatol* 2000;27:1241-6.
2. Schattman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopy study. *J Rheumatol* 1995;22:680-3.
3. Moll JM, Wright V. Psoriatic arthritis. *Semin Arthritis Rheum*

- 1973;3:55-78.
4. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. *Rheumatology Oxford* 2004;43:85-8.
 5. Dockerty JL, Williamson L, Wordsworth BP. Endomysial antibodies in psoriatic arthritis patients. *Rheumatology Oxford* 2002;41:1195-6.
 6. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. *Aliment Pharmacol Ther* 2000;14:1553-9.
 7. Kennedy TM, Jones RH, Hungin AP, O'Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. *Gut* 1998;43:770-4.
 8. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. *Br J Dermatol* 1982;106:323-30.
 9. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. *Am J Gastroenterol* 1990;85:962-3.
 10. Rahman P, Bartlett S, Siannis F, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. *Am J Hum Genet* 2003;73:677-81.